• 1
    Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 21236.
  • 2
    Ioachim HL, Pambuccian S, Giancotti F, et al. Reactivity of lung tumors with lung-derived and non-lung-derived monoclonal antibodies. Int J Cancer: Suppl 1994; 8: 1323.
  • 3
    Santamaría M, López-Beltrán A, Toro M, et al. Specific monoclonal antibodies against leukocyte-restricted cell surface molecule CD43 react with nonhematopoietic tumor cells. Cancer Res 1996; 56: 35269.
  • 4
    Pallant A, Ezkenazi A, Mattei M-G, et al. Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16. Proc Natl Acad Sci USA 1989; 86: 132832.
  • 5
    Shelley CS, Remold-O'Donnell E, Davis AE, III, et al. Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott–Aldrich syndrome. Proc Natl Acad Sci USA 1989; 86: 281928.
  • 6
    Remold-O'Donnell E, Kenney DM, Parkman R, et al. Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott–Aldrich syndrome. J Exp Med 1984; 159: 170523.
  • 7
    Andersson CX, Fernandez-Rodriguez J, Laos S, et al. CD43 has a functional NLS, interacts with β-catenin, and affects gene expression. Biochem Biophys Res Commun 2004; 316: 1217.
  • 8
    Seo W, Ziltener HJ. CD43 processing and nuclear translocation of CD43 cytoplasmic tail are required for cell homeostasis. Blood 2009; 114: 356777.
  • 9
    Rosenstein Y, Santana A, Pedraza-Alva G. CD43, a molecule with multiple functions. Immunol Res 1999; 20: 8999.
  • 10
    Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Ann Rev Immunol 2009; 27: 33962.
  • 11
    Fernandez-Rodriguez J, Andersson CX, Laos S, et al. The leukocyte antigen CD43 is expressed in different cell lines of nonhematopoietic origin. Tumor Biol 2002; 23: 193201.
  • 12
    Kadaja-Saarepuu L, Laos S, Jääger K, et al. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 and ARF. Oncogene 2008; 27: 170515.
  • 13
    Caron G, Delneste Y, Aubry JP, et al. Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα-dependent cytotoxic activity. Eur J Immunol 1999; 29: 358895.
  • 14
    Ostberg JR, Barth RK, Frelinger JG. The Roman god Janus: a paradigm for the function of CD43. Immunol Today 1998; 19: 54650.
  • 15
    Cyster JG, Shotton DM, Williams AF. The dimensions of the T-lymphocyte glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation. EMBO J 1991; 10: 893902.
  • 16
    Hernandez JD, Nguyen JT, He J, et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 2006; 177: 532836.
  • 17
    Brown TJ, Shuford WW, Wang W-C, et al. Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells. J Biol Chem 1996; 271: 2768695.
  • 18
    He Y-W, Bevan MJ. High level expression of CD43 inhibits T cell receptor/CD3-mediated apoptosis. J Exp Med 1999; 190: 19038.
  • 19
    Todeschini AR, Nunes MP, Pires RS, et al. Costimulation of host T lymphocytes by a trypanosomal trans-sialidase: involvement of CD43 signaling. J Immunol 2002; 168: 51928.
  • 20
    Kim HJ, Park HJ, Park WS, et al. CD43 cross-linking increases the Fas-induced apoptosis through induction of Fas aggregation in Jurkat T-cells. Exp Mol Med 2006; 38: 35763.
  • 21
    Brown WRA, Barclay AN, Sunderland CA, et al. Identification of a glycoprotein-like molecule at the cell surface of rat thymocytes. Nature 1981; 289: 45660.
  • 22
    Ardman B, Sikorski MA, Staunton DE. CD43 interferes with T-lymphocyte adhesion. Proc Natl Acad Sci USA 1992; 89: 50015.
  • 23
    Soler M, Merant C, Servant C, et al. Leukosialin (CD43) behavior during adhesion of human monocytic THP-1 cells to red blood cells. J Leukoc Biol 1997; 61: 60918.
  • 24
    Fukuoka M, Fukudome K, Yamashita Y, et al. Antiadhesive function of 130-kd glycoform of CD43 expressed in CD4 T-lymphocyte clones and transfectant cell lines. Blood 2000; 96: 426775.
  • 25
    Rosenstein Y, Park JK, Hahn WC, et al. CD43, a molecule defective in Wiskott–Aldrich syndrome, binds ICAM-1. Nature 1991; 354: 2335.
  • 26
    Stöckl J, Majdic O, Kohl P, et al. Leukosialin (CD43)-major histocompatibility class I molecule interactions involved in spontaneous T cell conjugate formation. J Exp Med 1996; 184: 176979.
  • 27
    van den Berg TK, Nath D, Ziltener HJ, et al. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J Immunol 2001; 166: 363740.
  • 28
    Matsumoto M, Atarashi K, Umemoto E, et al. CD43 functions as a ligand for E-selectin on activated T cells. J Immunol 2005; 175: 804250.
  • 29
    Remold-O'Donnell E, Rosen FS. Proteolytic fragmentation of sialophorin (CD43). Localization of the activation-inducing site and examination of the role of sialic acid. J Immunol 1990; 145: 33728.
  • 30
    Campanero MR, Pulido R, Alonso JL, et al. Down-regulation by tumor necrosis factor-α of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur J Immunol 1991; 21: 30458.
  • 31
    Bazil V, Strominger JL. CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes. Proc Natl Acad Sci USA 1993; 90: 37926.
  • 32
    Mambole A, Baruch D, Nusbaum P, et al. The cleavage of neutrophil leukosialin (CD43) by cathepsin G releases its extracellular domain and triggers its intramembrane proteolysis by presenilin/γ-secretase. J Biol Chem 2008; 283: 2362735.
  • 33
    Da Silva N, Bharti A, Shelley CS. HnRNP-K and Purα act together to repress the transcriptional activity of the CD43 gene promoter. Blood 2002; 100: 353644.
  • 34
    Shelley CS, Da Silva N, Teodoridis JM. During U937 monocytic differentiation repression of the CD43 gene promoter is mediated by the single-stranded DNA binding protein Purα. Br J Haematol 2001; 115: 15966.
  • 35
    Sánchez-Mateos P, Campanero MR, del Pozo MA, et al. Regulatory role of CD43 leukosialin on integrin-mediated T-cell adhesion to endothelial and extracellular matrix ligands and its polar redistribution to a cellular uropod. Blood 1995; 86: 222839.
  • 36
    Serrador JM, Nieto M, Alonso-Lebrero JL, et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell–cell contacts. Blood 1998; 91: 463244.
  • 37
    Sabri S, Soler M, Foa C, et al. Glycocalyx modulation is a physiological means of regulating cell adhesion. J Cell Sci 2000; 113: 1589600.
  • 38
    Seveau S, Keller H, Maxfield FR, et al. Neutrophil polarity and locomotion are associated with surface redistribution of leukosialin (CD43), an antiadhesive membrane molecule. Blood 2000; 95: 246270.
  • 39
    Piller F, Piller V, Fox RI, et al. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis. J Biol Chem 1988; 263: 1514650.
  • 40
    Tomlinson-Jones A, Federsppiel B, Ellies LG, et al. Characterization of the activation-associated isoform of CD43 on murine T lymphocytes. J Immunol 1994; 153: 342639.
  • 41
    Sikut R, Nilsson O, Baeckström D, et al. Colon adenoma and cancer cells aberrantly express the leukocyte-associated sialoglycoprotein CD43. Biochem Biophys Res Commun 1997; 238: 61216.
  • 42
    Sikut R, Andersson CX, Sikut A, et al. Detection of CD43 (leukosialin) in colon adenoma and adenocarcinoma by novel monoclonal antibodies against its intracellular domain. Int J Cancer 1999; 82: 528.
  • 43
    Woo VL, Bhuiya T, Kelsch R. Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 495500.
  • 44
    Seethala RR, Pasha TL, Raghunath PN, et al. The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol 2008; 16: 16572.
  • 45
    Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010; 102: 46474.
  • 46
    Andersson CX, Fernandez-Rodriguez J, Laos S, et al. Shedding and γ-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem J 2005; 387: 37784.
  • 47
    Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 127.